Provexis (PXS) AI Stock Analysis

• Market Cap: £22.87M
• Dividend Yield: N/A
• Average Volume (3M): 426.62K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.57
• Revenue Growth: 61.13%
• EPS Growth: 33.33%
• Country: UK
• Employees: 2
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): N/A
• Shares Outstanding: 2,345,891,400
• 10 Day Avg. Volume: 0
• 30 Day Avg. Volume: 426,617
• PEG Ratio: 0.68
• Price to Book (P/B): 7.92
• Price to Sales (P/S): 7.95
• P/FCF Ratio: -30.33
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: 0.98 p ▲(37.32% Upside)
• Action: Reiterated Date: 03/18/26
• Date: Action: Reiterated 03/18/26

The score is held back primarily by ongoing losses and continued cash burn despite improving revenue trends, with weak near-term technical momentum adding further pressure. A debt-free balance sheet provides some stability, but valuation is constrained by negative earnings and no stated dividend yield.

Positive Factors

Debt-free balance sheet

A zero-debt balance sheet materially lowers refinancing and interest-rate risk, giving Provexis flexibility to fund commercialization or absorb short-term cash burn without immediate reliance on external lenders. This structural strength supports strategic options over the next several months while revenues scale.

Negative Factors

Persistent negative cash flow

Consistent negative operating and free cash flow creates ongoing funding risk and may force dilutive equity raises or constrained investments. Even with improving top-line trends, continued cash burn undermines independent growth and can limit the company's ability to scale partner relationships or fund regulatory/commercial milestones.

Provexis Business Overview & Revenue Model

Company Description

Provexis plc, together with its subsidiaries, develops, licenses, and markets functional foods, medical foods, and dietary supplements worldwide. Its products include Fruitflow, a tomato extract that reduces the propensity for aberrant blood clott...

Read more

Provexis plc, together with its subsidiaries, develops, licenses, and markets functional foods, medical foods, and dietary supplements worldwide. Its products include Fruitflow, a tomato extract that reduces the propensity for aberrant blood clott...

How the Company Makes Money

Provexis makes money primarily by commercialising its Fruitflow® functional ingredient. Revenue is generated through business-to-business arrangements where third parties incorporate Fruitflow® into their own consumer products (e.g., dietary suppl...

Read more

Provexis makes money primarily by commercialising its Fruitflow® functional ingredient. Revenue is generated through business-to-business arrangements where third parties incorporate Fruitflow® into their own consumer products (e.g., dietary suppl...

Provexis Financial Statement Overview

Breakdown	Sep 2024	Mar 2023	Sep 2022	Sep 2021	Sep 2020
Income Statement
Total Revenue	1.29M	801.96K	389.92K	426.17K	505.33K
Gross Profit	532.94K	283.80K	294.42K	380.05K	456.19K
EBITDA	-449.63K	-603.59K	0.00	0.00	0.00
Net Income	-452.72K	-586.24K	-385.24K	-224.25K	-341.01K
Balance Sheet
Total Assets	1.01M	498.04K	845.99K	1.13M	1.29M
Cash, Cash Equivalents and Short-Term Investments	708.09K	189.36K	379.12K	863.87K	1.08M
Total Debt	0.00	0.00	0.00	0.00	0.00
Total Liabilities	248.21K	307.45K	188.34K	157.91K	150.68K
Stockholders Equity	1.30M	724.34K	1.19M	1.50M	1.66M
Cash Flow
Free Cash Flow	-338.90K	-191.50K	-519.85K	-213.79K	-262.32K
Operating Cash Flow	-338.90K	-191.50K	-519.85K	-213.54K	-262.07K
Investing Cash Flow	1.93K	1.73K	887.00	78.00	-250.00
Financing Cash Flow	857.63K	0.00	35.10K	1.05M	1.05M

Provexis Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.71
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:PXS, the sentiment is Negative. The current price of 0.71 is below the 20-day moving average (MA) of 1.10, below the 50-day MA of 1.22, and below the 200-day MA of 0.84, indicating a neutral trend. The MACD of -0.05 indicates Positive momentum. The RSI at 33.08 is Neutral, neither overbought nor oversold. The STOCH value of 44.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:PXS.

Provexis Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EAH	76 Outperform	£62.34M	-44.80	3.55%	―	1.44%	359.79%
STX	63 Neutral	£91.88M	-1.10	206.44%	―	93.48%	51.18%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PXS	45 Neutral	£22.87M	-11.67	-51.21%	―	61.13%	33.33%
CHLL	42 Neutral	£2.35M	-1.61	―	―	―	―